Pub. Date : 2004 Nov
PMID : 15312980
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). | Sildenafil Citrate | phosphodiesterase 5A | Homo sapiens |
| 2 | Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). | Sildenafil Citrate | phosphodiesterase 5A | Homo sapiens |
| 3 | Two commercialized PDE5 inhibitors, sildenafil and vardenafil, are being used to treat erectile dysfunction. | Sildenafil Citrate | phosphodiesterase 5A | Homo sapiens |
| 4 | Although these are the only two structural differences, vardenafil has more than 20-fold greater potency than sildenafil for inhibiting purified PDE5. | Sildenafil Citrate | phosphodiesterase 5A | Homo sapiens |
| 5 | The IC50 of methyl-sildenafil for inhibiting PDE5 indicated that it was 64 times less potent than demethyl-vardenafil, which was similar to the finding that, based on IC50, sildenafil was 40 times less potent than vardenafil. | Sildenafil Citrate | phosphodiesterase 5A | Homo sapiens |
| 6 | Similarly, the EC50 of methyl-sildenafil for inhibiting [3H]vardenafil binding to PDE5 indicated that it was 84 times less potent than demethyl-vardenafil, while the EC50 for sildenafil indicated that it was 31 times less potent than vardenafil. | Sildenafil Citrate | phosphodiesterase 5A | Homo sapiens |